Digoxin: Difference between revisions
Ostermayer (talk | contribs) (Text replacement - "Category:Drugs" to "Category:Pharmacology") |
Neil.m.young (talk | contribs) (Text replacement - "== " to "==") |
||
| Line 20: | Line 20: | ||
**Pediatric | **Pediatric | ||
== Indications == | ==Indications == | ||
*RVR control in a-fib/flutter, PSVT | *RVR control in a-fib/flutter, PSVT | ||
Revision as of 04:09, 5 July 2016
General
- Type: Cardiac glycoside
- Dosage Forms: PO, IV, IM
- Common Trade Names: Digitek, Digox, Lanoxin (US)
Adult Dosing
- Loading dose = 0.25 mg IV q2hr until effect (max total = 1.5 mg)
- in acute afib rvr with heart failure = 0.5 mg IV, then 0.25 mg IV q4hr until effect or max 1.5mg
Pediatric Dosing
Special Populations
- Pregnancy Rating:
- Lactation risk:
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Indications
- RVR control in a-fib/flutter, PSVT
Contraindications
- Allergy to class/drug
- WPW
- Increases conduction velocity in atrial tissue
Adverse Reactions
- GI: N/V, diarrhea, abd pain
- CV: Bradycardia, SA/AV block, ventr arrhythmias
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Kinetics
- Onset of action = 1.5-4hr (IV)
Mechanism of Action
- Inhibits Na+/K+ ATPase in the myocardium[1]
- Causes increase in intracellular sodium levels
- Results in reversal of sodium-calcium exchanger
- Normally imports three extracellular sodium ions into the cardiac myocyte in exchange for one intracellular calcium being exported
- Sodium accumulates intracellularly and is exchanged for Calcium.
- Causes an increase in the intracellular calcium concentration increasing contractility
- Also a lengthening of phase 4 and phase 0 of the cardiac action potential which ultimately decreases heart rate
- Summary
- Inhibits NaK pump
- Positive inotropy
- Negative chronotropy/dromotropy
- Indirect vagal stimulator
- Inhibits NaK pump
Comments
See Also
References
- ↑ Gheorghiade M. et al. Digoxin in the Management of Cardiovascular Disorders. Circulation. 2004; 109: 2959-2964
